News Focus
News Focus
icon url

biomaven0

11/13/11 4:21 PM

#130964 RE: jq1234 #130961

safety and long term data are more important to get market share



I completely agree. It's still much too early to say whether or not pona will ever get any share of 1st line. Its market for the mid-term is going to be 3rd-line and some 2nd-line.

Peter
icon url

rkrw

11/13/11 4:30 PM

#130965 RE: jq1234 #130961

fwiw. Sprycel+Tasigna are now annualizing at > $1.8b/year even though Gleevec is still dominating front line..